1 citations
,
October 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This case report describes a patient developing hidradenitis suppurativa-like lesions after undergoing gamma secretase complex inhibitor therapy for desmoid tumours, illustrating potential skin toxicity linked to the treatment.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reports that 71% of patients treated with the gamma-secretase inhibitor PF-03084014 for desmoid tumors experienced dermatologic side effects, such as follicular lesions and pruritic eruptions, which were managed with topical or systemic treatments.
April 2024 in “Biosaintifika Journal of Biology & Biology Education” In this study, researchers observed that a topical gel containing 20% hypoxia mesenchymal stem cell secretome significantly reduced IL-15 and IFN-γ mRNA expression and baldness by 60% in male Wistar rats with fluconazole-related alopecia.
This study found that adipose derived stem cells in areas of alopecia in patients with androgenetic alopecia showed different levels of various signaling proteins compared to other scalp and periumbilical regions.
1 citations
,
February 2022 in “Experimental Dermatology” This study found that the secretory profiles of adipose-derived stem cells vary between balding and non-balding scalp areas in androgenetic alopecia patients, suggesting involvement of angiogenic and inflammatory processes in the condition's development.